Unique investment vehicle provides efficient access to equity capital

独特的投资工具提供高效获取股权资本的途径

Outstanding debt of the original Note lowered by approximately 43%

原票据的未偿债务降低约43%

No issuance of common stock or dilutive warrants

不发行普通股或稀释性认股权证

LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) --

新泽西州劳伦斯维尔，2026年9月29日（环球电讯社）--

IMUNON, Inc. (Nasdaq: IMNN), (“IMUNON” or the “Company”), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of the Company’s newly designated, non-convertible Series B Preferred Stock.

IMUNON, Inc.（纳斯达克股票代码：IMNN）（以下简称“IMUNON”或“公司”）是一家开发DNA介导免疫疗法的临床阶段生物技术公司，今日宣布已签订一项交换协议，根据该协议，120万美元的未偿债务以及应计未付利息被转换为公司新指定的不可转换B系列优先股股份。

The transaction reduces the Company’s outstanding debt by approximately 43% and increases stockholders’ equity while preserving financial flexibility, with no issuance of common stock or warrants..

该交易使公司未偿债务减少约43%，并在保持财务灵活性的同时增加股东权益，且不发行普通股或认股权证。

'This transaction reduces outstanding debt and increases our shareholder equity while minimizing dilution for existing shareholders,' said Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. 'By exchanging a portion of our outstanding debt for preferred equity, we reduce future cash obligations.

IMUNON 总裁兼首席执行官 Stacy R. Lindborg 博士表示：“此次交易在最大限度减少现有股东股权稀释的同时，降低了未偿债务并增加了我们的股东权益。通过将部分未偿债务转换为优先股，我们减少了未来的现金偿付义务。”

I want to thank our financing partner for their continued confidence in the promise of IMNN-001. We believe this structure better positions the Company to execute our clinical strategy while preserving future financial flexibility.'.

我要感谢我们的融资合作伙伴对IMNN-001前景的持续信任。我们相信，这一架构使公司能够更好地执行临床战略，同时保持未来的财务灵活性。

Pursuant to the Exchange Agreement, IMUNON issued 120 shares of Series B Preferred Stock, at a purchase price of $10,000 per share and a stated value of $12,000 per share, in exchange for $1.2 million of principal and accrued and unpaid interest outstanding under the A-1 Note. The Company has designated 200 shares of Series B Preferred Stock, which are not convertible into shares of common stock, and expects the shares to be classified as permanent equity.

根据《交换协议》，IMUNON 发行了 120 股 B 系列优先股，每股购买价格为 10,000 美元，每股设定价值为 12,000 美元，以交换 A-1 票据项下未偿还的 120 万美元本金及应计未付利息。公司已指定 200 股 B 系列优先股，该等股份不可转换为普通股，并预计将该等股份分类为永久权益。

The transaction does not provide the Company with additional cash proceeds..

该交易未为公司提供额外的现金收益。

The shares of Series B Preferred Stock were issued in a private placement in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The securities have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

B系列优先股股份系依据经修订的《1933年证券法》（以下简称“《证券法》”）项下的注册要求豁免，以私募方式发行。该等证券未根据《证券法》进行注册，除非完成注册或适用注册要求的豁免情形，否则不得在美国境内发售或出售。

Additional information regarding the transaction will be contained in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission..

有关该交易的更多信息将包含在公司向美国证券交易委员会提交的8-K表格当前报告中。

About IMUNON

关于 IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

IMUNON 是一家处于临床阶段的生物技术公司，致力于推进一系列创新疗法组合，这些疗法利用人体自然机制，针对多种人类疾病产生安全、有效且持久的治疗反应，形成了与传统疗法截然不同的差异化方法。

IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas.

IMUNON 正在其各种治疗模式中开发其非病毒 DNA 技术。首个治疗模式为 TheraPlas。

®

注册商标

, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine

，是为在实体瘤治疗中通过基因方式递送细胞因子和其他治疗性蛋白而开发的，其中免疫学方法被认为具有前景。第二种模式是PlaCCine

®

®

, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

，是为递送能够引发强烈免疫反应的病毒抗原基因而开发的。

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials, including one Phase 2 clinical trial (OVATION 2), and is currently being studied in a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.

公司的核心临床项目IMNN-001是一种基于DNA的免疫疗法，用于局部治疗晚期卵巢癌。该项目已完成多项临床试验，包括一项II期临床试验（OVATION 2），目前正在进行III期临床试验（OVATION 3）。IMNN-001的作用机制是指导机体在肿瘤部位产生安全且持久的强效抗癌分子，如白细胞介素-12和干扰素γ。

Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.

此外，公司已完成其新冠加强疫苗（IMNN-101）的首次人体研究的给药工作。公司将持续利用这些技术平台，并通过自主推进或合作的方式，不断拓展质粒DNA技术的前沿，以更好地服务于患有难治性疾病的患者。

For more information, please visit .

更多信息，请访问。

www.imunon.com

www.imunon.com

.

。

Forward-Looking Statements

前瞻性陈述

IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, the expected accounting treatment of the Series B Preferred Stock, the anticipated benefits of the transaction, and the Company's plans and expectations with respect to its development programs more generally, are forward-looking statements.

IMUNON 谨告知读者，本新闻稿中的前瞻性陈述是根据 1995 年《私人证券诉讼改革法案》的“安全港”条款作出的。除历史事实陈述外，所有陈述均为前瞻性陈述，包括但不限于对 B 系列优先股预期会计处理的说明、对交易预期收益的描述，以及公司对其开发计划更广泛的规划与预期。

We generally identify forward-looking statements by using words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, the Company's ability to satisfy its remaining obligations under the A-1 Note and its redemption obligations in respect of the Series B Preferred Stock; the possibility that the accounting treatment of the Series B Preferred Stock as permanent equity is subsequently revised; the Company's ability to maintain compliance with the continued listing requirements of The Nasdaq Stock Market; the Company's need to raise additional capital; uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, supp.

我们通常通过使用“可能”、“将”、“预期”、“计划”、“预计”、“估计”、“打算”等词语以及类似表述（以及其他提及未来事件、状况或情形的词语或表述）来识别前瞻性陈述。提醒读者注意，此类前瞻性陈述涉及风险和不确定性，包括但不限于：公司履行其在A-1票据项下剩余义务的能力及其对B系列优先股的赎回义务；B系列优先股作为永久权益的会计处理随后可能被修订的可能性；公司维持符合纳斯达克股票市场持续上市要求的能力；公司筹集额外资本的需求；与研发活动和临床试验过程中不可预见的变化相关的不确定性，包括中期结果不一定预示最终结果这一事实；分析中期临床数据的不确定性和困难；进行临床试验所涉及的重大费用、时间以及失败风险；IMUNON评估其未来发展计划的必要性；客户、供应商可能采取的行动。

Investor Contact

投资者联系

Valter Pinto

瓦尔特·平托

KCSA Strategic Communications

KCSA战略传播

212-896-1254

212-896-1254

imunon@kcsa.com

imunon@kcsa.com